20959881

Source:http://linkedlifedata.com/resource/pubmed/id/20959881

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001779, umls-concept:C0009566, umls-concept:C0016011, umls-concept:C0019080, umls-concept:C0030705, umls-concept:C0243077, umls-concept:C0332281, umls-concept:C0439234, umls-concept:C0522523, umls-concept:C1522318, umls-concept:C1948041
pubmed:issue	3
pubmed:dateCreated	2010-10-20
pubmed:abstractText	Treatment of symptomatic coronary artery disease with percutaneous intervention requires antithrombotic therapy. Patients with elevated thromboembolic risk benefit from therapy with glycoprotein IIb/IIIa inhibitors. The safety and effectiveness of glycoprotein IIb/IIIa inhibition have been well documented in clinical trials. Drug-induced bleeding complications in elderly patients have not been specifically addressed.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9715903
pubmed:status	PubMed-not-MEDLINE
pubmed:issn	1918-1515
pubmed:author	pubmed-author:BojaraWaldemarW, pubmed-author:EwersAydanA, pubmed-author:GermingAlfriedA, pubmed-author:GrewePeterP, pubmed-author:LawoThomasT, pubmed-author:LindstaedtMichaelM, pubmed-author:MüggeAndreasA
pubmed:issnType	Electronic
pubmed:volume	15
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	e57-60
pubmed:year	2010
pubmed:articleTitle	Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention.
pubmed:affiliation	Medical Clinic II, Cardiology and Angiology, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, University of Bochum, Bochum, Germany.
pubmed:publicationType	Journal Article